CY1118830T1 - Ενωσεις διμεθυλ-βενζοϊκου χρησιμες στην αντιμετωπιση φλεγμονωδων παθησεων - Google Patents

Ενωσεις διμεθυλ-βενζοϊκου χρησιμες στην αντιμετωπιση φλεγμονωδων παθησεων

Info

Publication number
CY1118830T1
CY1118830T1 CY20171100435T CY171100435T CY1118830T1 CY 1118830 T1 CY1118830 T1 CY 1118830T1 CY 20171100435 T CY20171100435 T CY 20171100435T CY 171100435 T CY171100435 T CY 171100435T CY 1118830 T1 CY1118830 T1 CY 1118830T1
Authority
CY
Cyprus
Prior art keywords
treatment
benzoic
dimethyl
inflammatory diseases
units useful
Prior art date
Application number
CY20171100435T
Other languages
English (en)
Inventor
Maria-Jesus Blanco-Pillado
Tatiana Natali Vetman
Matthew Joseph Fisher
Steven Lee Kuklish
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1118830T1 publication Critical patent/CY1118830T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/42Oxygen atoms attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/113Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ένωση του τύπου II, όπου Α είναι: * R1 είναι CH3, CF3 ή F, * R2 είναι Η, CH3 ή F, * R3 είναι CH3, OCH3, OH, F, R4 είναι OH ή CH2OH και * X είναι CH ή Ν. Οι ενώσεις αυτές είναι επιλεκτικοί αναστολείς των ΕΡ4 και είναι χρήσιμες στην αντιμετώπιση φλεγμονωδών παθήσεων, όπως η αρθρίτιδα.
CY20171100435T 2012-06-29 2017-04-12 Ενωσεις διμεθυλ-βενζοϊκου χρησιμες στην αντιμετωπιση φλεγμονωδων παθησεων CY1118830T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261665956P 2012-06-29 2012-06-29
US201361778969P 2013-03-13 2013-03-13
PCT/US2013/046685 WO2014004230A1 (en) 2012-06-29 2013-06-20 Dimethyl-benzoic acid compounds

Publications (1)

Publication Number Publication Date
CY1118830T1 true CY1118830T1 (el) 2018-01-10

Family

ID=48746667

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100435T CY1118830T1 (el) 2012-06-29 2017-04-12 Ενωσεις διμεθυλ-βενζοϊκου χρησιμες στην αντιμετωπιση φλεγμονωδων παθησεων

Country Status (41)

Country Link
US (2) US8642768B2 (el)
EP (1) EP2867218B1 (el)
JP (1) JP6114824B2 (el)
KR (1) KR101634032B1 (el)
CN (1) CN104334540B (el)
AP (1) AP4063A (el)
AR (1) AR091431A1 (el)
AU (1) AU2013280779B2 (el)
BR (1) BR112014029551A2 (el)
CA (1) CA2875572C (el)
CL (1) CL2014003537A1 (el)
CO (1) CO7160064A2 (el)
CR (1) CR20140554A (el)
CY (1) CY1118830T1 (el)
DK (1) DK2867218T3 (el)
DO (1) DOP2014000286A (el)
EA (1) EA025531B1 (el)
ES (1) ES2623099T3 (el)
GT (1) GT201400289A (el)
HK (1) HK1203936A1 (el)
HR (1) HRP20170540T1 (el)
HU (1) HUE032398T2 (el)
IL (1) IL236218A (el)
IN (1) IN2014MN02356A (el)
JO (1) JO3221B1 (el)
LT (1) LT2867218T (el)
ME (1) ME02655B (el)
MX (1) MX347476B (el)
MY (1) MY172860A (el)
NZ (1) NZ701894A (el)
PE (1) PE20150185A1 (el)
PH (1) PH12015500008A1 (el)
PL (1) PL2867218T3 (el)
PT (1) PT2867218T (el)
RS (1) RS55756B1 (el)
SG (1) SG11201408629QA (el)
SI (1) SI2867218T1 (el)
TN (1) TN2014000500A1 (el)
TW (1) TWI572597B (el)
WO (1) WO2014004230A1 (el)
ZA (1) ZA201408631B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110015221A1 (en) * 2003-12-23 2011-01-20 Pierre Fabre Medicament Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
TWI572597B (zh) * 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基-苯甲酸化合物
EP2765128A1 (en) * 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
EP3083554B1 (en) 2013-12-17 2019-03-13 Eli Lilly & Company Dimethylbenzoic acid compounds
CA2960324A1 (en) * 2014-09-09 2016-03-17 Bayer Pharma Aktiengesellschaft Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
TWI770157B (zh) * 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
WO2018189011A1 (de) * 2017-04-10 2018-10-18 Bayer Aktiengesellschaft Substituierte n-arylethyl-2-arylchinolin-4-carboxamide und ihre verwendung
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
KR102626982B1 (ko) 2017-05-18 2024-01-18 이도르시아 파마슈티컬스 리미티드 Pge2 수용체 조절제로서의 피리미딘 유도체
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
AU2018269666B2 (en) 2017-05-18 2022-02-03 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
PT3625224T (pt) 2017-05-18 2021-10-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-substituídos
WO2022102731A1 (ja) 2020-11-13 2022-05-19 小野薬品工業株式会社 Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
JP2000355551A (ja) * 1999-06-15 2000-12-26 Nikken Chem Co Ltd 医薬組成物
DE602004017481D1 (de) 2003-09-22 2008-12-11 Euro Celtique Sa Zur behandlung von schmerzen geeignete therapeutische mittel
EP1723132A1 (en) 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
US7705035B2 (en) * 2006-06-12 2010-04-27 Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands
JPWO2008123207A1 (ja) * 2007-03-26 2010-07-15 アステラス製薬株式会社 オルニチン誘導体
WO2012004293A2 (de) 2010-07-08 2012-01-12 Bayer Cropscience Ag Insektizide und fungizide wirkstoffkombinationen
WO2012117097A1 (en) 2011-03-03 2012-09-07 Universität des Saarlandes Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
TWI572597B (zh) * 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基-苯甲酸化合物

Also Published As

Publication number Publication date
CA2875572A1 (en) 2014-01-03
TN2014000500A1 (en) 2016-03-30
JO3221B1 (ar) 2018-03-08
EA025531B1 (ru) 2017-01-30
ZA201408631B (en) 2017-04-26
MY172860A (en) 2019-12-12
AU2013280779A1 (en) 2014-11-27
CA2875572C (en) 2016-03-22
US8933098B2 (en) 2015-01-13
EA201492140A1 (ru) 2015-10-30
RS55756B1 (sr) 2017-07-31
EP2867218A1 (en) 2015-05-06
ME02655B (me) 2017-06-20
SG11201408629QA (en) 2015-01-29
AR091431A1 (es) 2015-02-04
TW201410665A (zh) 2014-03-16
NZ701894A (en) 2016-09-30
CN104334540B (zh) 2016-03-16
PL2867218T3 (pl) 2017-07-31
AP4063A (en) 2017-03-09
US8642768B2 (en) 2014-02-04
PE20150185A1 (es) 2015-02-13
KR20150013335A (ko) 2015-02-04
IL236218A (en) 2017-12-31
WO2014004230A1 (en) 2014-01-03
HRP20170540T1 (hr) 2017-06-16
CN104334540A (zh) 2015-02-04
EP2867218B1 (en) 2017-02-22
US20140005222A1 (en) 2014-01-02
PT2867218T (pt) 2017-04-19
AU2013280779B2 (en) 2015-09-10
ES2623099T3 (es) 2017-07-10
HK1203936A1 (en) 2015-11-06
DOP2014000286A (es) 2015-01-31
MX347476B (es) 2017-04-27
KR101634032B1 (ko) 2016-06-27
US20140094491A1 (en) 2014-04-03
CO7160064A2 (es) 2015-01-15
DK2867218T3 (en) 2017-05-01
GT201400289A (es) 2015-05-28
IN2014MN02356A (el) 2015-08-14
JP2015522589A (ja) 2015-08-06
LT2867218T (lt) 2017-04-25
IL236218A0 (en) 2015-02-01
TWI572597B (zh) 2017-03-01
JP6114824B2 (ja) 2017-04-12
SI2867218T1 (sl) 2017-04-26
HUE032398T2 (en) 2017-09-28
MX2014015952A (es) 2015-07-17
AP2014008165A0 (en) 2014-12-31
CR20140554A (es) 2015-02-04
CL2014003537A1 (es) 2015-04-24
PH12015500008B1 (en) 2015-03-02
BR112014029551A2 (pt) 2017-06-27
PH12015500008A1 (en) 2015-03-02

Similar Documents

Publication Publication Date Title
CY1118830T1 (el) Ενωσεις διμεθυλ-βενζοϊκου χρησιμες στην αντιμετωπιση φλεγμονωδων παθησεων
CY1120104T1 (el) Αναστολεις της syk
CY1121549T1 (el) Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων
CY1121744T1 (el) Παραγωγα c4-μονομεθυλο-τριτερπενοειδους και μεθοδοι χρησης αυτων
CY1120705T1 (el) Καινοφανεις αναστολεις αποακετυλασων ιστονων
CR20140548A (es) Derivados de aril-sultamo como moduladores de rorc
UA110338C2 (en) Chemical compounds
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
MX342310B (es) Compuestos de tiazolopirimidina.
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
UY34523A (es) Derivados de betulina
EA200900945A1 (ru) Новый способ синтеза агомелатина
MX343561B (es) Compuestos de imidazolpiridazina.
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
UY33910A (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC
CR20140135A (es) Nuevos derivados de aril-quinolina
EA200900946A1 (ru) Новый способ синтеза агомелатина
EA201101675A1 (ru) Спироэпоксиды как промежуточные продукты синтеза
CY1120142T1 (el) Ενωσεις αζετιδινυλοξυφαινυλοπυρρολiδινης
MX349548B (es) Compuestos de tienopirimidina.
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
EA200900943A1 (ru) Новый способ синтеза агомелатина
EA201291235A1 (ru) Новые способы